These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27196064)

  • 21. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clopidogrel conundrum.
    Bertino JS
    J Clin Pharmacol; 2014 Aug; 54(8):841-2. PubMed ID: 25044099
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibitory kinetics of fruit components on CYP2C19 activity.
    Seki H; Akiyoshi T; Imaoka A; Ohtani H
    Drug Metab Pharmacokinet; 2019 Jun; 34(3):181-186. PubMed ID: 30979536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
    Boulenc X; Djebli N; Shi J; Perrin L; Brian W; Van Horn R; Hurbin F
    Drug Metab Dispos; 2012 Jan; 40(1):187-97. PubMed ID: 22004687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
    Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer.
    Dansette PM; Rosi J; Bertho G; Mansuy D
    Chem Res Toxicol; 2012 Feb; 25(2):348-56. PubMed ID: 22103858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
    Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
    J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
    JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Chen CH; Yang JC; Uang YS; Lin CJ
    Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine.
    Kim MJ; Jeong ES; Park JS; Lee SJ; Ghim JL; Choi CS; Shin JG; Kim DH
    Drug Metab Dispos; 2014 Jan; 42(1):141-52. PubMed ID: 24170778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.
    Ancrenaz V; Desmeules J; James R; Fontana P; Reny JL; Dayer P; Daali Y
    Br J Pharmacol; 2012 Aug; 166(8):2362-70. PubMed ID: 22428615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin.
    Wang X; Zhu HJ; Markowitz JS
    Biol Pharm Bull; 2015; 38(2):292-7. PubMed ID: 25747989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.